5.2. imaging investigations. renal tumours diagnosed abdominal us ct performed medical reasons (le: 3). renal masses classified solid cystic based imaging findings. 5.2.1. presence enhancement solid renal masses, important criterion differentiating malignant lesions presence enhancement (le: 3). traditionally, us, ct mri used detecting characterising renal masses. renal masses diagnosed accurately imaging alone. 5.2.2. computed tomography magnetic resonance imaging computed tomography mri used characterise renal masses. imaging must performed unenhanced, early arterial phase, parenchymal phase intravenous contrast material demonstrate enhancement. ct imaging, enhancement renal masses determined comparing hounsfield units (hu) before, after, contrast administration. change fifteen hu, more, solid tumour parts demonstrates enhancement thus vital tumour parts (le: 3). computed tomography mri allows accurate diagnosis rcc cannot reliably distinguish oncocytoma fat-free aml malignant renal neoplasms [109-112] (le: 3). abdominal ct provides information : function morphology contralateral kidney (le: 3);primary tumour extension;venous involvement;enlargement locoregional lns;condition adrenal glands solid organs (le: 3). abdominal contrast-enhanced ct angiography useful selected cases detailed information renal vascular supply needed . results ct indeterminate, ceus valuable alternative characterise renal lesions [117-120] (le: 1b). magnetic resonance imaging may provide additional information venous involvement extent ivc tumour thrombus poorly defined ct [121-124] (le: 3). mri, especially high-resolution t2-weighted images provide superior delineation uppermost tumour thrombus, inflow enhanced blood may reduced due extensive occlusive tumour thrombus growth ivc. t2-weighted image intrinsic contrast allows good delineation . magnetic resonance imaging indicated patients allergic intravenous ct contrast medium pregnancy without renal failure (le: 3). magnetic resonance imaging allows evaluation dynamic enhancement without radiation exposure. advanced mri techniques diffusion-weighted (dwi) perfusion-weighted imaging explored renal mass assessment . recently, use multiparametric mri (mpmri) diagnose ccrcc via clear cell likelihood score (ccls) srms reported . ccls 5-tier classification denotes likelihood mass representing ccrcc, ranging ‘very unlikely’ ‘very likely’. authors prospectively validated diagnostic performance ccls 57 patients ct1a tumours found high diagnostic accuracy. diagnostic performance mpmri-based ccls validated larger retrospective cohort (n = 434) across tumour sizes stages , ccls found independent prognostic factor identifying ccrcc. diagnosis complex renal cysts (bosniak iif–iii) mri may preferable. accuracy ct limited cases, poor sensitivity (36%) specificity (76%; κ = 0.11); mri, due higher sensitivity enhancement, showed 71% sensitivity 91% specificity (κ = 0.64). contrast-enhanced us showed high sensitivity (100%) specificity (97%), negative predictive value 100% (κ = 0.95) . younger patients worried radiation exposure frequent ct scans, mri may offered alternative although limited data exist correlating diagnostic radiation exposure development secondary cancers . sr meta-analysis compared diagnostic performance ceus vs. contrast-enhanced ct (cect) contrast-enhanced mri (cemri) assessment benign malignant cystic solid renal masses. sixteen studies included pooled analysis. results suggested comparable diagnostic performance ceus compared cect (pooled sensitivity 0.96 [95% ci: 0.94-0.98], vs. 0.90 [95% ci: 0.86-0.93], studies final diagnosis benign malignant renal masses pathology), ceus vs. cemri (pooled sensitivity 0.98 [95% ci: 0.94-1.0], vs. 0.78 [95% ci: 0.66-0.91], studies final diagnosis pathology report reaffirmed diagnosis follow-up imaging without pathology report). however, significant limitations data, including studies cemri, clinical statistical heterogeneity inconsistency, high risks confounding. 5.2.3. investigations emerging technologies renal arteriography inferior venacavography limited role work-up selected rcc patients (le: 3). patients sign impaired renal function, isotope renogram total renal function evaluation considered optimise treatment decision-making (le: 2a). 18fdg positron-emission tomography (pet) recommended primary staging. (le: 1b). emerging technologies differentiation rcc subtypes growing body evidence regard prostate-specific membrane antigen (psma) positron emission tomography (pet)-ct , 99tc sestamibi spect/ct 89zr-dfo-girentuximab pet-ct . additionally modalities evaluated staging purposes . currently, level published evidence sufficient terms external validation allow guideline recommedation made. 5.2.4. radiographic investigations evaluate rcc metastases chest ct accurate chest staging [90,91,134-136] (le: 3). use nomograms calculate risk lung metastases proposed based tumour size, clinical stage presence systemic symptoms . based large, retrospective datasets, suggest chest ct may omitted patients ct1a cn0, without systemic symptoms, anaemia thrombocythemia, due low incidence lung metastases (< 1%) group patients. consensus bone metastases symptomatic diagnosis; thus, routine bone imaging generally indicated (le: 3). however, bone scan, brain ct, mri may used presence specific clinical laboratory signs symptoms (le: 3). prospective comparative blinded study involving 92 consecutive mrcc patients treated first-line vascular endothelial growth factor receptor (vegfr)-tyrosine kinase inhibitor (tki) (median follow-up 35 months) found whole-body dwi/mri detected statistically significant higher number bony metastases compared conventional thoraco-abdomino-pelvic contrast-enhanced ct, higher number metastases independent prognostic factor progression-free survival (pfs) overall survival (os) . incidence brain metastasis without neurological symptoms retrospectively evaluated 1,689 mrcc patients, selected included 68 clinical trials 2001-2013 . patients mandatory brain screening ct/mri. seventy-two patients (4.3%) diagnosed occult brain metastases, 39% multi-focal. patients (61%) international metastatic renal cancer database consortium (imdc) intermediate risk 26% favourable risk. majority (86%) patients > 2 extracranial metastatic sites, including lung metastases 92%. predominantly radiotherapy, performed 93% patients, median os 10.3 months (range 7.0–17.9 months) observed. 5.2.5. bosniak classification renal cystic masses system classifies renal cysts five categories, based ct imaging appearance, predict malignancy risk (le: 3), also advocates treatment category (table 5.1). updated bosniak classification (2019) strengthened classification included mri diagnostic criteria ; however, requires validation. according meta-analysis based 471 patients, risk maliganacy bosniak iif-iii, may higher old classification . validation, imaging report therefore identify classification used. lastly, management cystic renal tumours also discussed section 3.5.8. table 5.1: bosniak classification renal cysts updated 2019 bosniak classification /imaging modalityctmri1 (benign)well-defined, thin (≤ 2 mm) smooth wall; homogeneous simple fluid (-9 20 hu); septa calcifications; wall may enhancewell-defined, thin (≤ 2 mm) smooth wall; homogeneous simple fluid (signal intensity similar csf); septa calcifications; wall may enhance2 (benign)1. cystic masses thin (≤ 2 mm) (1–3) septa; septa wall may enhance; may calcification type2. homogeneous hyperattenuating (≥ 70 hu) masses non-contrast ct3. homogeneous non-enhancing masses. 20 hu renal mass protocol ct, may calcification type†4. homogeneous masses -9 20 hu non-contrast ct5. homogeneous masses 21 30 hu portal venous phase ct6. homogeneous low-attenuation masses small characterise1. cystic masses thin (≤ 2 mm) (1-3) enhancing septa; non-enhancing septa; may calcification type2. homogeneous masses markedly hyperintense t2-weighted imaging (similar csf) non-contrast mri3. homogeneous masses markedly hyperintense t1-weighted imaging (approximately 32.5 normal parenchymal signal intensity) non-contrast mri2f (follow-up, five years. malignant.)cystic masses smooth minimally thickened (3 mm) enhancing wall, smooth minimal thickening (3 mm) one enhancing septa, many (≥ 4 mm) smooth thin (≤ 2 mm) enhancing septa1. cystic masses smooth minimally thickened (3 mm) enhancing wall, smooth minimal thickening (3 mm) one enhancing septa, many (≥ 4 mm) smooth thin (≤2 mm) enhancing septa2. cystic masses heterogeneously hyperintense unenhanced fat-saturated t1-weighted imaging3 (surgery – see chapter 7. 50% malignant.)one enhancing thick (≥ 4 mm width) enhancing irregular (displaying ≤ 3 mm obtusely margined convex protrusion[s]) walls septaone enhancing thick (≥ 4 mm width) enhancing irregular (displaying ≤ 3 mm obtusely margined convex protrusion[s]) walls septa4 (surgery. malignant.)one enhancing nodule(s) (≥4 mm convex protrusion obtuse margins, convex protrusion size acute marginsone enhancing nodule(s) (≥4 mm convex protrusion obtuse margins, convex protrusion size acute margins)